NHS England threatened legal action against Oxford University hospitals trust
April 4, 2019Medical Communications, Research and Development Hopsitals, NHS, NHS England, OUH, cancer screening, patients
NHS England threatened to sue Oxford University hospitals (OUH) NHS trust after they objected to the former’s controversial decision to …
Sorrento Therapeutics seek $1 billion from billionaire biotech investor Patrick Soon-Shiong
April 4, 2019Business Services, Sales and Marketing Abraxane, Celgene, Cynviloq, Patrick Soon-Shiong, Sorrento, lawsuits
Sorrento Therapeutics is seeking $1 billion in damages from billionaire biotech investor Patrick Soon-Shiong, owner of US newspaper the LA …
European approval for Pfizer’s Vizimpro in first-line non-small cell lung cancer
April 4, 2019Sales and Marketing Cancer, Europe, Pfizer, Vizimpro, lung cancer, non small cell lung cancer, non-small cell lung cancer, pharma
The European Commission has awarded marketing approval to Pfizer’s tyrosine kinase inhibitor (TKI) Vizimpro (dacomitinib), it has emerged, as a …
HPV vaccine prevents 90% of cervical pre-cancer cases in Scotland, research shows
April 4, 2019Research and Development HPV, Scotland, cervical cancer, immunity, vaccines, virus
Routine vaccination of girls in Scotland against HPV has led to a dramatic drop in cases of cervical cancer, according …
Sangamo and Pfizer’s gene therapy increases FVIII activity in severe haemophilia A in early study
April 3, 2019Research and Development, Sales and Marketing Pfizer, Sangamo, haemophilia, pharma
Sangamo Therapeutics and Pfizer have unveiled new Phase 1/2 data for their jointly developed investigational gene therapy SB-525, demonstrating that …
Children born in poverty show major differences in brain function, study shows
April 3, 2019Research and Development India, UEA, brain development, brain function, childhood, children
Children born into poverty show major differences in early brain function, according to research from the University of East Anglia. …
Clovis Oncology’s Rubraca shows promise in multiple pancreatic tumour mutations, interim data show
April 3, 2019Research and Development Cancer, Clovis Oncology, Pancreatic cancer, Rubraca, oncology, pharma
At the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Clovis Oncology took the opportunity to present …
Janssen closes plant in California, 49 positions axed
April 3, 2019Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, Vacaville, california
Janssen are letting go of 49 employees due to the closure of their plant in Vacaville, California. The Johnson & …
NHS gender pay gap has increased since last year
April 3, 2019Research and Development NHS, NHS trusts, analysis, gender pay gap, salary
The gender pay gap has worsened in the NHS, according to analysis from The Guardian, which found the gender pay …
Novartis’ Cosentyx approved in China for plaque psoriasis
April 2, 2019Manufacturing and Production, Sales and Marketing China, Cosentyx, Novartis, pharma, psoriasis
Novartis has revealed that its interleukin-17A (IL-17A) Cosentyx (secukinumab) has been authorised for use in China in the treatment of …
NICE recommends Eli Lilly’s Verzenio in combination with Fulvestrant for breast cancer
April 2, 2019Manufacturing and Production CDF, Cancer, NICE, breast cancer, britain, oncology
Britain’s cost effectiveness body, the National Institute for Health and Care Excellence (NICE), has recommended Eli Lilly’s Verzenio (abemaciclib) in …
Teva’s Ajovy injection secures EU approval for the prevention of migraine
April 2, 2019Manufacturing and Production, Sales and Marketing EU, Europe, Teva, ajovy, migraine, pharma
Teva has announced that its calcitonin gene-related peptide (CGRP) inhibitor Ajovy (fremanezumab) has been awarded marketing authorisation by the European …
China approves Keytruda for non-small cell lung cancer
April 2, 2019Manufacturing and Production China, MSD, Merck and Co, USA, keytruda, lung cancer, pharma
US firm MSD has won approval for Keytruda in China. The cancer immunotherapy has thus become the first PD-1 inhibitor …
Novartis must face kickback allegations in court
April 2, 2019Manufacturing and Production Novartis, US, government, kickbacks, prescriptions, whistle blower, whistle-blower
The US government has accused Novartis of paying doctors millions of dollars in kickbacks as part of a “company-wide kickback …
Artios Pharma name experienced oncologist as company’s new CMO
April 1, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Artios Pharma, CMO, Cancer, DDR, oncology
British biotech Artios Pharma have appointed experienced oncologist Dr Ian Smith, as the company’s new Chief Medical Officer (CMO). Dr …
How I learned to stop worrying and love the placebo effect
April 1, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing clinical trials, feature, pharma, placebo effect
Louis Goss talks to Harvard Medical School placebo expert Dr Ted Kaptchuk in asking what the placebo effect means for …
CHMP recommendation for bluebird bio’s gene therapy in β-thalassaemia
April 1, 2019Research and Development, Sales and Marketing Bluebird Bio, CHMP, EMA, Zynteglo, gene therapy, β-thalassaemia
Massachusetts-based bluebird bio has taken a significant leap forward in its pursuit of regulatory authorisation for its first gene therapy, …
Indian authorities say J&J’s baby shampoo contains ‘harmful ingredients’
April 1, 2019Sales and Marketing Cancer, India, J&J, JJ, Johnson & Johnson, Rajasthan, baby shampoo, formaldehyde
Indian authorities in the state of Rajasthan have said that samples taken from Johnson & Johnson’s baby shampoo contained ‘harmful …
Novartis inks $1.6 billion deal with immunology biotech IFM Therapeutics
April 1, 2019Sales and Marketing Atlas Venture, Boston, IFM Therapeutics, Novartis, pharma
Swiss firm Novartis has agreed to pay a sum of $310 million upfront to Boston inflammation specialist IFM Therapeutics, as …
Roche’s Tecentriq combo shows promise in first-line triple-negative breast cancer
April 1, 2019Research and Development, Sales and Marketing Cancer, Roche, breast cancer, pharma, tecentriq
Roche has revealed new Phase 1b data on a new Tecentriq combo, showing early promise in the first-line treatment of …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
